Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use. Surveyed primary care physicians say that a therapy's effect on overall irritable bowel syndrome symptoms is the attribute that most influences their prescribing decisions in non-constipation predominant irritable bowel syndrome.

The new report entitled Irritable Bowel Syndrome: A New Therapy for Non-Constipation-Predominant IBS with Greatly Improved Efficacy Will Reach Near-Blockbuster Status also finds that both Lotronex and Tioga/Ono's asimadoline will earn Decision Resources' clinical gold standard status for non-constipation predominant irritable bowel syndrome for 2013 and 2018, following the launch of asimadoline in 2013.

"Lotronex is currently Decision Resources' clinical gold standard for the treatment of non-constipation predominant irritable bowel syndrome because it has better efficacy than other current therapies, particularly on treating overall symptoms -- the attribute that most influences prescribing physicians," said Decision Resources Analyst Dancella Fernandes, M.B.A., Ph.D. "Although only in early clinical trials, asimadoline will share the clinical gold standard status once it is available in 2013 based on available clinical data and thought leader opinion, and will likely garner a greater patient share than Lotronex following its launch."

About the Report

Irritable Bowel Syndrome: A New Therapy for Non-Constipation-Predominant IBS with Greatly Improved Efficacy Will Reach Near-Blockbuster Status is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                        Decision Resources, Inc.   Lisa Osgood                               Christopher Comfort   781-296-2606                              781-296-2597   losgood@hl-isy.com                        ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Decision Resources: Lisa Osgood, +1-781-296-2606,
losgood@hl-isy.com, or Decision Resources, Inc.: Christopher Comfort,
+1-781-296-2597, ccomfort@dresources.com

Uptake of Reformulations of Conventional Analgesics Will Drive Annual Three Percent Growth in the Acute Pain Drug Market Through 2018

View Now